olanzapine and melatonin
PreclinicalSmall molecule
olanzapine and melatonin is one of 24 small molecule programs targeting Schizoaffective Disorder. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
23 competitors in Schizoaffective Disorder
#DrugCompanyPhaseTrials
1Risperdal
WWim Janssens
Approved
Zyprexa
MMODAG GmbH
Approved
Nicorette
PfizerApproved
Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Abilify
OtsukaApproved
Epidiolex
Jazz PharmaceuticalsApproved
Estrace
Novo NordiskApproved
Diamox
TevaApproved
Haldol
DDePuy Orthopaedics
Approved
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for olanzapine and melatonin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details